The abstract is read at the publisher; the summary is JClub's.
Sentinel lymph node biopsy after neoadjuvant chemotherapy in locally advanced breast cancer had a 2.1% sentinel lymph node false-negative rate (95% CI 0.1–12.7) with adequate mapping.
- Why it matters: Accurate axillary staging after neoadjuvant chemotherapy is needed for patients who become cN0, because false negatives can leave residual nodal disease undetected.
- What they did: In a prospective cohort, patients with cT4 and/or cN2/N3 breast cancer who were cN0 after NAC underwent dual-tracer SLNB, followed by completion axillary lymph node dissection; FNR used adequate mapping criteria.
- The result: Among 87 patients with adequate mapping, nodal pathologic complete response was 46%, and in 47 with residual nodal disease one false-negative SLN produced an FNR of 2.1%, supporting SLNB for axillary staging after NAC downstaging.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.